Literature DB >> 24816255

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.

Miwako Kakiuchi1, Takashi Nishizawa2, Hiroki Ueda3, Kengo Gotoh3, Atsushi Tanaka4, Akimasa Hayashi4, Shogo Yamamoto5, Kenji Tatsuno5, Hiroto Katoh6, Yoshiaki Watanabe7, Takashi Ichimura4, Tetsuo Ushiku4, Shinichi Funahashi2, Keisuke Tateishi8, Ikuo Wada9, Nobuyuki Shimizu9, Sachiyo Nomura9, Kazuhiko Koike8, Yasuyuki Seto9, Masashi Fukayama4, Hiroyuki Aburatani5, Shumpei Ishikawa10.   

Abstract

Diffuse-type gastric carcinoma (DGC) is characterized by a highly malignant phenotype with prominent infiltration and stromal induction. We performed whole-exome sequencing on 30 DGC cases and found recurrent RHOA nonsynonymous mutations. With validation sequencing of an additional 57 cases, RHOA mutation was observed in 25.3% (22/87) of DGCs, with mutational hotspots affecting the Tyr42, Arg5 and Gly17 residues in RHOA protein. These positions are highly conserved among RHO family members, and Tyr42 and Arg5 are located outside the guanine nucleotide-binding pocket. Several lines of functional evidence indicated that mutant RHOA works in a gain-of-function manner. Comparison of mutational profiles for the major gastric cancer subtypes showed that RHOA mutations occur specifically in DGCs, the majority of which were histopathologically characterized by the presence of poorly differentiated adenocarcinomas together with more differentiated components in the gastric mucosa. Our findings identify a potential therapeutic target for this poor-prognosis subtype of gastric cancer with no available molecularly targeted drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816255     DOI: 10.1038/ng.2984

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  36 in total

1.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

Authors:  M F Olson; H F Paterson; C J Marshall
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

2.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

3.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

4.  Transforming mutations of RAC guanosine triphosphatases in human cancers.

Authors:  Masahito Kawazu; Toshihide Ueno; Kenji Kontani; Yoshitaka Ogita; Mizuo Ando; Kazutaka Fukumura; Azusa Yamato; Manabu Soda; Kengo Takeuchi; Yoshio Miki; Hiroyuki Yamaguchi; Takahiko Yasuda; Tomoki Naoe; Yoshihiro Yamashita; Toshiaki Katada; Young Lim Choi; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

5.  Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors.

Authors:  Xun Shang; Fillipo Marchioni; Chris R Evelyn; Nisha Sipes; Xuan Zhou; William Seibel; Matthew Wortman; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?

Authors:  J Stiekema; A Cats; A Kuijpers; F van Coevorden; H Boot; E P M Jansen; M Verheij; O Balague Ponz; M Hauptmann; J W van Sandick
Journal:  Eur J Surg Oncol       Date:  2013-03-15       Impact factor: 4.424

7.  Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type.

Authors:  Donald Earl Henson; Christopher Dittus; Mamoun Younes; Hong Nguyen; Jorge Albores-Saavedra
Journal:  Arch Pathol Lab Med       Date:  2004-07       Impact factor: 5.534

Review 8.  Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway.

Authors:  Patricia C Salinas
Journal:  Trends Cell Biol       Date:  2007-07-20       Impact factor: 20.808

9.  Mathematical analysis of copy number variation in a DNA sample using digital PCR on a nanofluidic device.

Authors:  Simant Dube; Jian Qin; Ramesh Ramakrishnan
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

10.  Studying copy number variations using a nanofluidic platform.

Authors:  Jian Qin; Robert C Jones; Ramesh Ramakrishnan
Journal:  Nucleic Acids Res       Date:  2008-08-18       Impact factor: 16.971

View more
  211 in total

1.  Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells.

Authors:  Changhwan Yoon; Soo-Jeong Cho; Bülent Arman Aksoy; Do Joong Park; Nikolaus Schultz; Sandra W Ryeom; Sam S Yoon
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?

Authors:  Masahiro Maeda; Toshikazu Ushijima
Journal:  Gastric Cancer       Date:  2015-08-22       Impact factor: 7.370

3.  Cancer gene profiling explores the possible precision medicine for diffuse-type gastric adenocarcinoma.

Authors:  Marin Ishikawa; Hideyuki Hayashi; Naoya Sakamoto; Shinya Tanaka; Hiroshi Nishihara
Journal:  Med Oncol       Date:  2019-11-25       Impact factor: 3.064

Review 4.  Next generation sequencing-based emerging trends in molecular biology of gastric cancer.

Authors:  Renu Verma; Prakash C Sharma
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 5.  Molecular subtypes in cancers of the gastrointestinal tract.

Authors:  Maarten F Bijlsma; Anguraj Sadanandam; Patrick Tan; Louis Vermeulen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

Review 6.  Recognition of and recent issues in hereditary diffuse gastric cancer.

Authors:  Shinya Sugimoto; Hirokazu Komatsu; Yuichi Morohoshi; Takanori Kanai
Journal:  J Gastroenterol       Date:  2015-06-07       Impact factor: 7.527

7.  Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival.

Authors:  Cristina Díaz Del Arco; Lourdes Estrada Muñoz; Elena Molina Roldán; Mª Ángeles Cerón Nieto; Luis Ortega Medina; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

Review 8.  Rho GTPases: Regulation and roles in cancer cell biology.

Authors:  Raquel B Haga; Anne J Ridley
Journal:  Small GTPases       Date:  2016-09-14

9.  Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma.

Authors:  Marin Kato; Hiroshi Nishihara; Hideyuki Hayashi; Taichi Kimura; Yusuke Ishida; Lei Wang; Masumi Tsuda; Mishie Ann Tanino; Shinya Tanaka
Journal:  Med Oncol       Date:  2016-12-10       Impact factor: 3.064

10.  Variegated RHOA mutations in adult T-cell leukemia/lymphoma.

Authors:  Yasunobu Nagata; Kenji Kontani; Terukazu Enami; Keisuke Kataoka; Ryohei Ishii; Yasushi Totoki; Tatsuki R Kataoka; Masahiro Hirata; Kazuhiro Aoki; Kazumi Nakano; Akira Kitanaka; Mamiko Sakata-Yanagimoto; Sachiko Egami; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Yusuke Shiozawa; Tetsuichi Yoshizato; Hiromichi Suzuki; Ayana Kon; Kenichi Yoshida; Yusuke Sato; Aiko Sato-Otsubo; Masashi Sanada; Wataru Munakata; Hiromi Nakamura; Natsuko Hama; Satoru Miyano; Osamu Nureki; Tatsuhiro Shibata; Hironori Haga; Kazuya Shimoda; Toshiaki Katada; Shigeru Chiba; Toshiki Watanabe; Seishi Ogawa
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.